Disseminated superficial actinic porokeratosis (DSAP) is a chronic skin condition that produces small, ring-shaped spots on sun-exposed areas of the body. It is the most common form of porokeratosis, typically appearing after age 30, and primarily affects fair-skinned women. The spots themselves are usually harmless, but they carry a small risk of turning into skin cancer over time, which makes monitoring important.
What DSAP Looks Like
DSAP lesions show up as brownish or reddish, slightly raised spots that range from about 3 millimeters to 2 centimeters across. Their most distinctive feature is a thin, thread-like ridge around the outer edge, almost like a tiny ring or border raised just above the surrounding skin. Multiple spots typically appear in a symmetrical pattern on both sides of the body, clustering on the forearms, lower legs, shoulders, and other areas that get regular sun exposure. The face and palms are usually spared.
Individual spots can merge together into larger irregular patches over time. They tend to be more noticeable in summer and may fade slightly during winter months, reflecting the role sunlight plays in driving the condition.
Causes and Genetics
DSAP develops from a combination of genetic susceptibility and cumulative sun exposure. Ultraviolet radiation is the primary environmental trigger. Both UVA and UVB rays damage skin cell DNA and suppress local immune defenses in the skin, which helps explain why lesions concentrate on sun-exposed areas and why people who are immunosuppressed (such as organ transplant recipients) develop the condition more frequently and more severely.
On the genetic side, researchers have identified mutations in the gene responsible for producing mevalonate kinase, an enzyme critical to a metabolic pathway that cells rely on for several essential functions. One of those functions is producing cholesterol, which plays a key role in maintaining the skin’s barrier. The same pathway also helps regulate how skin cells produce keratin, the protein that makes up the outer layer of skin. When mevalonate kinase doesn’t work properly, skin cells in affected areas grow abnormally, producing the characteristic ring-shaped lesions. The condition follows an autosomal dominant inheritance pattern, meaning a parent with DSAP has a 50% chance of passing the genetic predisposition to each child, though sun exposure is still needed to trigger lesion development.
Who Gets DSAP
The condition mainly affects fair-skinned women and typically first appears in the third or fourth decade of life. Onset before age 30 is uncommon. While most cases develop by middle age, late-onset DSAP has been documented in patients as old as their 70s and beyond. Case reports of elderly patients show a strong female predominance, with women outnumbering men roughly five to one in some series. A family history of porokeratosis is common, and cases of mothers and daughters both developing the condition have been well documented.
How DSAP Is Diagnosed
DSAP can be tricky to identify on appearance alone because it closely resembles actinic keratosis, the rough, scaly patches caused by sun damage that are far more common. Both conditions share features like abnormal skin cells, inflammation, and flaky surface changes. The key difference is structural: DSAP lesions have a sharply defined border with a specific microscopic feature that actinic keratoses lack.
That feature is called the cornoid lamella, and it is the defining hallmark of all forms of porokeratosis. Under the microscope, the cornoid lamella appears as a diagonal column of abnormal, flattened skin cells sitting at the edge of the lesion, right where the raised ridge is visible to the naked eye. Beneath this column, the normal granular layer of the skin is thinned or completely absent, and scattered dying skin cells are visible. A skin biopsy that reveals this structure confirms the diagnosis. In DSAP specifically, the abnormal cell changes are concentrated at the lesion’s border rather than spread across the entire spot, which helps distinguish it from actinic keratosis, where the changes tend to be more widespread.
Risk of Skin Cancer
DSAP lesions can, in a minority of cases, transform into squamous cell carcinoma or, less commonly, basal cell carcinoma. Older estimates put the malignant transformation rate for DSAP at around 3.4%, making it lower than other forms of porokeratosis like the linear type, which carries a risk as high as 19%. However, a more recent single-center study looking at 18 years of data found that 29% of their DSAP patients eventually developed a malignancy within their lesions. The wide range between these figures likely reflects differences in follow-up duration and how actively the patients were monitored.
The practical takeaway is that while most DSAP lesions will never become cancerous, the risk is real enough to justify regular skin checks. Any lesion that starts to change rapidly, becomes thickened, ulcerates, or feels different from the others warrants a biopsy.
Treatment Options
DSAP has historically been difficult to treat. Most available options are used off-label and focus on either destroying individual lesions or reducing inflammation. These include cryotherapy (freezing), carbon dioxide laser ablation, topical chemotherapy creams, photodynamic therapy, retinoids, and anti-inflammatory gels. Results with these approaches have generally been inconsistent. Cryotherapy and laser treatments can work for isolated spots but aren’t practical when dozens or hundreds of lesions are scattered across large areas, and they carry a risk of scarring. Studies on photodynamic therapy for DSAP have produced contradictory results, with some patients responding well and others showing no improvement at all.
A more targeted approach has emerged from the understanding that DSAP involves a breakdown in the mevalonate pathway. A 2023 randomized clinical trial tested a topical cream containing 2% lovastatin, a cholesterol-lowering compound that acts on the same metabolic pathway disrupted by the genetic mutation. Over 12 weeks, patients using the lovastatin cream saw their disease severity drop by roughly 50%, with no serious side effects. Adding cholesterol to the cream did not improve results, suggesting lovastatin alone may be sufficient. While this is still an emerging treatment and not yet widely available, it represents the first therapy designed to address the underlying biology of DSAP rather than simply removing lesions one at a time.
Living With DSAP
Because cumulative UV exposure drives both the appearance of new lesions and the progression of existing ones, consistent sun protection is the most important long-term strategy. This means broad-spectrum sunscreen on exposed skin, protective clothing, and limiting time in direct sunlight during peak hours. These measures won’t reverse existing spots, but they can slow the development of new ones.
DSAP is a lifelong condition. Lesions don’t resolve on their own, and treated spots can recur. Many people find the cosmetic appearance more bothersome than any physical symptoms, though some experience mild itching, particularly in warm weather. Regular dermatological follow-up allows for monitoring of any lesions that might be changing in ways that suggest early malignant transformation, catching problems when they’re still straightforward to address.